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Summary: If the effect of a treatment carries on after the treatment is withdrawn then the response to a
second treatment may well be due in part to the previous treatment. This so called carry-over effect may bias
any clinical trial in which subjects are tested more than once. Cross-over studies can be routinely checked for
this bias. In other study designs, however, common sense and alertness for unusual patterns in the data are
the only defences against it.
The amount of carry-over bias in clinical trials can be somewhat minimized by the following measures. Dose-
response studies, dose-titration studies, and open evaluation studies should require a sufficient washout period
between the administrations of the drugs. Studies using duplicate standard deviations for the estimation of
intra-individual reproducibility of a test should routinely include a statistical test for differences between the
duplicate data. Self-controlled studies should not be used otherwise than as an initial orientation for a new
treatment. Parallel studies should routinely be stratified for symmetry of previous treatments. Studies with
subjective variables are frequently influenced by psychological carry-over effects and should, therefore, be
validated together with objective variables whenever possible.
In spite of the above measures many cases of carry-over effect remain unpreventable.
introduction f _ , _ . . . . . . .cross-overs, but also any other type of clinical trial m
If the effect of one treatment carries on after the which subjects are tested more than once,
treatment is withdrawn then the response to a second
treatment may well be due in part to the previous
treatment. This is the so-called carry-over effect. It is ^ D Λ r\ τ·* *· c·* j-• , , . t „ „ Dose Response and Dose Titration Studiesusually thought of as a physical carry-over effect of
a compound in the blood stream. However, another A dose-effect relationship is commonly derived from
real possibility is that of psychological carry-over. The the effects following a series of incremental doses of
term was first used in conjunction, with cross-over a drug. A dose-response study estimates this effect by
trials (1 —4), where each patient serves as his own the use of mean scores. A dose titration study does
control. Procedures have been developed to test for so by the fraction of responders. In classical receptor
carry-over effects in such studies (5 — 12). From them theory it is assumed that the drug effect is propor-
one may conclude that the carry-over effect may have tional to the fraction of receptors occupied by the
a large impact on the final results and may largely drug and that maximal effect occurs when all recep-
invalidate these studies. The Food and Drug Admin- tors are occupied. The Michaelis Menten equation
istration (FDA) (13) and some statisticians (1, 14— explains the shape of the dose response and dose
17) even discouraged the use of cross-overs because titration curves,
of this potential bias. Using the standard phase 1—4
classification of clinical trials (11, 18, 19) (tab. 1), we pff _ Maximal effect χ Dose
demonstrate that carry-over effect may not only bias ~~ Constant + Dose
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Tab. 1. Phase 1—4 classification of clinical trials
Characteristics Popular study designs
Phase 1—2 · Normal volunteers
β Pharmacokinetics, biologic effects, dose titration
Phase 2—3 ο Small groups of patients
ο Therapeutic efficacy and safety
Phase 3—4 β Large groups of patients





















Fig. 1. Dose (D) response curves with ( ) and without (—)
carry-over effect due to accumulation of residual drug.
KD = dose needed to obtain half-maximal effect.
This equation describes a simple hyperbola with the
maximal effect being approached asymptotically. In
order to display a wide range of drug concentrations
more easily, log dose is frequently plotted instead of
dose. Thus, the result is the familiar sigmoidal log
dose-effect curve (fig. 1). Anomalous relationships
may result from different causes, e.g., a maximal
response from less than maximal receptor occupancy
(spare receptors), from a threshold phenomenon or
from the presence of competitive agents in the blood.
Anomalous curves, especially very steep ones (fig. 1),
may be caused by the carry-over effect because of the
following. In dose response studies the subjects are
generally tested several times. The second experiment
usually takes place after 4 plasma half-times of the
drug that is being tested. Figure 2 shows that even
after 4 half-times the plasma concentration is not yet
zero and that after a two-fold dose the plasma con-
centration at 4 half-times is equally two-fold. In ad-
dition, a significant receptor occupancy may last
longer than 4 plasma half-times. These effects, al-
though assumed by statisticians (20), are not routinely
taken into account by investigators. The result would
be an over-estimation of treatment effect and rec-
ommendation of erroneously low doses in follow-up
0 2 4
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Fig. 2. Patterns to illustrate the influence of a two-fold differ-
ence in dosage. Q = concentration of drug in plasma




















Fig. 3. Dose-response study of respectively 5, 10, and 20 mg
phenoxybenzamine and finger temperature after stan-
dard cooling 4 in patients with Raynautfs syndrome
(n = 16). Solid lines present mean results ± SD's of
tests performed with 4 plasma half-time intervals be-
tween the tests, dotted line with 14 plasma half-times.
studies, giving rise to insufficient results. To test these
assumptions we performed a 4ose^response study of
different doses of the vasodilator phenoxybenzamine
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on finger temperature after standard finger cooling
(21) in patients with Raynaucfs disease (fig. 3). With
14 plasma half-time intervals between the subsequent
doses the mean dose-response relationship was sig-
nificantly flatter (dotted curve). An interval of 4
plasma half-times was apparently not sufficient to
prevent a significant carry-over effect (solid curve).
Studies with Duplicate Standard Deviations
Reproducibility of a test may be expressed as the
coefficient of variation. This method, however, meas-
ures reproducibility in general and not specifically
intra-individual reproducibility. For study designs
with repeated measurements in a single subject an a
priori assessment of the intra-individual reproducibil-
ity of the main variables is required. For that purpose
duplicate standard deviations are frequently used. All
subjects are tested twice. The duplicate standard de-
viations are calculated according to:
S =
S = duplicate standard deviation
Vi = difference between test 1 and 2 in subject i
n = number of subjects
Table 2 gives a hypothesized example of such a pro-
cedure. In the left column there is a significant dif-
ference between test 1 and 2. In the right there is not.
Still both columns have the same duplicate standard
deviations. The significant difference between test 1
and 2 in the left column is probably due to the carry-
over effect, provided that the investigators kept the
study circumstances of test series 1 and 2 unchanged.
From the example it can be seen that the duplicate
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standard deviations cannot differentiate between ran-
dom effects and carry-over bias. We recommend,
therefore, that one always combines duplicate stan-
dard deviation calculations with a statistical test for
differences between the duplicates. If a significant
difference is detected, the use of duplicate standard
deviations has little value because it does not represent
intra-individual reproducibility, but mainly carry-over
bias.
Open Evaluation Studies
Carry-over effects may also occur when different com-
pounds are administered one after another. Even com-
pletely new and unexpected effects may result from
interactions between the different compounds that are
present in the blood stream together. For example,
we studied the effects of different adrenergic receptor
agonists and antagonists on the blood pressure of
normotensive subjects. Phenoxybenzamine hardly in-
fluenced the blood pressure, whereas epinephrine
caused a substantial rise in blood pressure (fig. 4).
Time
Fig. 4. Response of blood pressure to epinephrine with and
without prior administration of phenoxybenzamine
(lower and upper record respectively).
However, when epinephrine was given after phenoxy-
benzamine, the pressor effect turned into a depressor.
This effect was explained by a carry-over effect of
phenoxybenzamine, which blocked the vasoconstric-
tive -receptors and give rise to the ß-vasodilator
effect of epinephrine. Similarly, an enhanced pressor
effect of epinephrine can be observed after pretreat-
inent with propranolol, which is a compound that
otherwise lowers the blood pressure. Such interactions
are common in everyday clinical practice where sick
subjects are given a number of drugs until equilibrium
is restored. It is, of course, impossible to evaluate the
effects of the separate compounds in these situations.
Eur. J. Clin. Chem. Clin: Biochem. / Vol. 31,1993 / No. 12
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It is, however, essential to do so in open evaluation
studies of new pharmacological compounds. In such
studies a number of newly developed compounds is
given shortly one after another to a single subject or
a small group of subjects. This is done for the purpose
of obtaining a fast selection of a few compounds for
further study. Because of economic reasons such stud-
ies are frequently uncontrolled. They should at least
have appropriate washout periods between two tests,
as dose-response and dose-titration studies require.
Otherwise, the results are likely to be biased by carry-
over effects.
Cross-Over Studies
Table 3 shows the basic design of a cross-over study.
Group A receives the test compound in the first pe-
riod, followed by a placebo or standard therapy.
Group B receives the two treatments in the reverse
order. In the analysis the data of the test compound
periods are taken together and compared with the
data of the placebo or standard therapy periods
(a + d versus c + b). Physical carry-over effect oc-
curs when a treatment is used for curing an ailment
rather than for alleviation. Suppose the test com-
pound is an antibiotic (tab. 4). After period 1, 100%
of the patients in group A and 0% of the patients in
group B are cured. After the next period, finally all
patients are cured. In the analysis the difference be-
tween antibiotic and placebo in group A is zero; in
group B it is 100% — mean value 50% improvement.
Obviously a cross-over design should never be used
when a treatment cures a disease. However, with
symptomatic therapies as well small curative effects
can occur, e. g., wound healing by vasodilators. This
is illustrated by a study of Kahan (22) (tab.5). The
efficacy of a vasodilator was assessed in patients with
Raynaud s syndrome. Group A took the placebo after
Tab. 4. Model of cross-over study with antibiotic or placebo











Percentage of cured patients.
Tab. 3. Study designs
Cross-over study




































Group A New a
therapy
Group B Standard b
therapy
* Instead of standard therapy, a placebo is frequently used.
Tab. 5. Efficacy of vasodilator or placebo in a cross-over study
in patients with RaynaucFs syndrome (22)









Group A Vasodi- 24.0 ±11.0 Placebo 25.0 ± 10.8
(n = 10) lator
Group B Placebo 34.3 ± 14.9 Vasodi- 23.1 ± 19.1
(n = 10) lator
* Mean frequency of Raynaud attacks per week ± S. D.
the vasodilator. The frequency of Raynaud attacks
was only 25 attacks per week. Group B has the pla-
cebo first. The score is not less than 34.3 attacks,
which is significantly different from 25 (p < 0.05).
Analyzing the data according to the cross-over design
we find an improvement in group A of — 1 attack,
and in group B of —11.2 attacks, for a mean im-
provement — 6.1 attacks. But when we just left out
period 2 and compared the data of the first period,
the improvement is —10.3 attacks. So the cross-over
gives a more than 40% underestimation compared
with the first period. This is probably largely due to
a physical carry-over effect in group A. The beneficial
vasodilator effect in this group seems to carry on after
the compound has been withdrawn and replaced by
a placebo.
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 12
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Self-Controlled Studies
These are studies where a single group of patients is
given a standard treatment and a new treatment, one
after the other (tab. 3). As with cross-over studies a
carry-over effect from period 1 into period 2 is pos-
sible. However, an additional problem is that since a
control group is missing here data cannot be tested
for it. The next problem is that self-controlled studies
are more often used at early points in the development
of new treatments (23), so that we have few clinical
arguments against carry-over effect. An additional
weakness of such studies is the general use of large
numbers of variables (23), which enhances the chances
of a type II error, which yields a difference where
there is none, and of a confounding of dependent and
independent variables because multivariate analysis is
rarely applied. This means that self-controlled trials
should not be used otherwise than as an initial ori-
entation for a new treatment. One exception is the
situation where a trial is designed in order to detect
carry-over effect. E. g., Packer et al. (24) used a self-
controlled study to investigate the clinical reaction of
patients with heart failure to acute withdrawal of
nitroprusside. The self-controlled design seems ideal
for the establishment of this rebound phenomenon,
which can be considered as a special form of carry-
over effect (24).
Parallel-Group Studies
In parallel-group studies two groups of patients re-
ceive a different treatment throughout the trial (tab.
3). Because there is no change-over of therapy during
the trial, carry-over effects within the trial are ex-
cluded. However, carry-over effects from treatments
prior to the trial are not and may bias parallel studies
to a greater extent than they do cross-overs. The point
is that the between-group comparison of parallel stud-
ies is much more dependent on symmetry of the
treatment groups than the within-group comparison
of cross-overs. This can be illustrated by a parallel-
group study of Graham on the effect of positive-
Tab. 6. Patients' characteristics in a two-group parallel study
of positive-pressure ventilation treatment for pneumo-
nia (25)




















pressure or sham ventilation on patients with pneu-
monia (25). The treatment group was significantly
better than the control group. Although three of the
four covariates were almost evenly split between the
treatment groups, the fourth (prior antibiotic treat-
ment) was somewhat lopsided (tab. 6). Because prior
antibiotic therapy was likely to have had a clinically
large effect on outcome, the imbalance could easily
have biased the results. We recommend that during
randomization parallel groups should not only rou-
tinely be stratified for symmetry of covariates such as
age, sex, duration of sickness but also for symmetry
of previous treatments.
Studies with Subjective Variables
Another real possibility is that of psychological carry-
over. This can be illustrated by a simple cross-over
design (tab. 3). A less active agent is compared with
an effective one and both treatments are judged by a
subjective variable, e.g., improvement of complaints.
In the first period with the effective agent most pa-
tients feel reduction in complaints. They approach the
second with confidence. The other group experiences
little improvement and gets a bad feeling about the
trial. This influences its appraisal of the second period.
Table 7 gives an example: Group A received a new
effective vasodilator before standard therapy and had
a better score than Group B, 2.2 versus 1.8 points
(new vasodilator Group A versus Group B, p < 0.05).
The difference between the new and standard therapy
in Group A was 2.2 — 1.2 = 1.0 point. In group B
1.8 — 1.2 = 0.6 points — for a mean value of 0.8
points. But when we forget about period 2 and com-
pare the data of the first period, the improvement is
2.2 — 1.2 =1.0 point. So this cross-over gives an
underestimation of some 20%. This is probably due
to a psychological carry-over effect in Group B. The
patients in this group are disappointed and this im-
pairs their appraisal of the second period. This ex-
Tab. 7. Efficacy of two vasodilators in a cross-over study in
patients with RaynaucTs syndrome (26)





Group A New 2.2 ± 0.8 Standard 1.2 ± 0.9
vasodilator vasodilator
Group B Standard 1.2 ± 0.8 New 1.8 ± 0.6
vasodilator vasodilator
* Mean improvement of Raynaud complaints ± S. DM judged
by a 4-point clinical scale (0 = no improvement; 4 = com-
plete relief).
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ample deals with the psychological carry-over effect
in a cross-over design. The test subject's attitude to a
study is, however, a variable hard to control in any
study design. For example, most of the placebo-con-
trolled parallel studies will have run in periods either
with placebo or with an active agent. This may sim-
ilarly cause either a negative or a positive psycholog-
ical carry-over effect from the very start. Moreover,
the subjects of the placebo arm of the study may lose
their motivation during the trial, giving rise to un-
derestimation of the final result of this arm rather
than proper estimation of it. Also cohort or case-
control studies using multiple questionnaires may suf-
fer from this type of gradual demotivation bias, which
has hardly been given any attention by the scientific
community. Psychological carry-over effects can, of
course, be minimized by the use of objective variables
(e.g., physical measurements like blood pressure,
heart rate, temperature). Subjective variables are,
however, frequently indispensible and may even be
the only ones that count. What good is a treatment
if it does not make you feel better? A defence against
the potential bias from psychological carry-over ef-
fects is alertness to unusual patterns of answers. Un-
fortunately, there is generally no statistical method of
testing for it. Further, the value of subjective data
should be validated together with objective variables
and be interpreted with caution.
Discussion
Carry-over effect occurs when the response to a sec-
ond treatment is in part due to the previous part of
the study. It was first described in connection with
cross-over studies (1 —4). From previous statistical
reports one may conclude that it may have a large
impact on the final results and may largely invalidate
these studies (3, 4, 14, 16). The present paper shows
that substantial carry-over bias may also occur in any
other type of study where subjects are treated more
than once, while there are virtually no methods to
test for it. There is, therefore, little one can do to
address the bias in these situations. The following
recommendations may be considered by investigators:
1. Cross-over studies should routinely include a sta-
tistical test for carry-over bias. Simple methods for
this purpose are the Grizzle test (1) or the "look
at the data method" (9, 27).
2. In other study designs no test is available. Clinical
arguments and alertness to unexpected patterns in
the data are the only defences against it so far.
3. Dose-response, dose-titration, and open evaluation
studies should require sufficient washout periods
between the administrations of the drugs. Even as
many as 14 plasma half-times may be required.
4. Studies using duplicate standard deviations should
always be combined with a statistical test for dif-
ferences between the duplicate data. If a significant
difference is detected, the use of duplicate standard
deviations for the estimation of intra-individual
reproducibility has little value.
v"?-
5. Self-controlled studies should not be used other-
wise than as an initial orientation for a new treat-
ment.
6. Parallel studies should routinely be stratified for
symmetry of previous treatments.
7. Subjective variables are frequently exposed to psy-
chological carry-over effects. They should, there-
fore, be validated together with objective variables
whenever possible. If not, they should be inter-
preted with caution.
8. As many cases of carry-over bias seem unprevent-
able, we shall simply have to live with them.
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